Blog Band – PharmaShots

05

Shots: The US FDA has accepted NDA of oral Wegovy for chronic weight management & major adverse CV events risk reduction in adults with obesity or overweight & comorbidities (PDUFA:…

05

7 minutes ago

News

Endogenex Reports REGENT-1 Australian Clinical Study Data of ReCET System for Type 2 Diabetic Duodenopathy

Shots: Endogenex has reported REGENT-1 Australian study data of ReCET System for the treatment of inflamed & dysfunctional tissue associated with type 2 diabetic (T2D) duodenopathy; REGENT-1 is also being…

05

20 minutes ago

News

Chengdu Origen and Vanotech Report the First Patient Dosing in P-I (VAN-2401) Trial of KH658 for Wet Age-related Macular Degeneration

Shots: Chengdu Origen & Vanotech has reported the first pts dosing in Vanotech-led P-I (VAN-2401) trial assessing KH658 for wet age-related macular degeneration (wet AMD) in the US The P-I trial…

05

29 minutes ago

News

Recursion Presents Preliminary P-Ib/II (TUPELO) Trial Data of REC-4881 for Familial Adenomatous Polyposis (FAP) at DDW 2025

Shots: P-Ib/II (TUPELO) trial (enrolment ongoing) assessed REC-4881 (4 or 8mg, QD) in FAP, with P-II evaluating efficacy via upper & lower endoscopy at Wk. 0, 13 (on-treatment), & 25…

05

4 hours ago

News

Merck Animal Health’s Mometamax Single Receives the US FDA’s Approval to Treat Dogs with Otitis Externa

Shots: The US FDA has approved Mometamax Single (gentamicin, posaconazole, & mometasone furoate otic suspension) to treat otitis externa in dogs; commercially available by the summer of 2025 Mometamax Single…

02

3 days ago

Video

LIFE SCIENCES | DAILY NEWS | MAY 02, 2025 | PHARMASHOTS

02

3 days ago

News

Repare Therapeutics Out-Licenses its Discovery Platforms to DCx Biotherapeutics

Shots: Repare has out-licensed its discovery platform incl. SNIPRx, SNIPRx-surf, & STEP2 , along with certain intellectual property to DCx As per the deal, Repare will get $4M as upfront &…

02

3 days ago

News

AstraZeneca Reports P-III (LOGOS & KALOS) Trial Findings of Breztri Aerosphere for Uncontrolled Asthma

Shots: AstraZeneca has reported P-III (LOGOS & KALOS) trial results evaluating Breztri Aerosphere (BGF; 320/28.8/9.6μg or 320/14.4/9.6μg) vs PT009 (ICS/LABA via Aerosphere) & Symbicort pressurized metered-dose inhaler (pMDI) in pts (n=~4400) with…

02

3 days ago

News

Merck Animal Health Collaborates with AmacaThera to Develop Long-Acting Injectable Formulations for Veterinary Use

Shots: Merck Animal Health has entered into a binding evaluation & option agreement with AmacaThera to develop long-acting formulations for veterinary use Collaboration will leverage AmacaThera’s AmacaGel hydrogel platform to…

02

3 days ago

News

Bavarian Nordic Reports the MHRA’s Approval of Vimkunya to Prevent Chikungunya

Shots: The UK’s MHRA has approved Vimkunya for active immunization against CHIKV disease in individuals (≥12yrs.); launch expected in the summer of 2025. Application submitted to Health Canada, with potential…

Novo Nordisk Reports the US FDA’s NDA Acceptance of Oral Wegovy for Weight Management

Endogenex Reports REGENT-1 Australian Clinical Study Data of ReCET System for Type 2 Diabetic Duodenopathy

Recursion Presents Preliminary P-Ib/II (TUPELO) Trial Data of REC-4881 for Familial Adenomatous Polyposis (FAP) at DDW 2025

Merck Animal Health’s Mometamax Single Receives the US FDA’s Approval to Treat Dogs with Otitis Externa

LIFE SCIENCES | DAILY NEWS | MAY 02, 2025 | PHARMASHOTS

Repare Therapeutics Out-Licenses its Discovery Platforms to DCx Biotherapeutics

AstraZeneca Reports P-III (LOGOS & KALOS) Trial Findings of Breztri Aerosphere for Uncontrolled Asthma

Merck Animal Health Collaborates with AmacaThera to Develop Long-Acting Injectable Formulations for Veterinary Use

Bavarian Nordic Reports the MHRA’s Approval of Vimkunya to Prevent Chikungunya

Contact US

FOLLW US

FOLLW US

Sign Up to Our Newsletter